FAQ on Tonix Pharmaceuticals and Makana Therapeutics Xenotransplantation Research Collaboration

What is the purpose of the collaboration between Tonix Pharmaceuticals and Makana Therapeutics?

The collaboration aims to evaluate TNX-1500, Tonix’s anti-CD40L monoclonal antibody candidate, in preclinical studies alongside Makana’s human-compatible organs and cells, to support a future investigational new drug application to the FDA for compassionate use in xenotransplantation.

Why is this collaboration significant?

This collaboration is significant because it positions both companies to advance potential treatments for organ failure through novel transplant solutions, leveraging Makana’s genetically engineered pigs designed for improved human compatibility.

How does TNX-1500 contribute to xenotransplantation research?

TNX-1500, as an anti-CD40L monoclonal antibody candidate, is being evaluated for its potential to prevent organ transplant rejection, which is crucial for the success of xenotransplantation.

Who is involved in this research collaboration?

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Makana Therapeutics are the key entities involved in this research collaboration.

What are the expected outcomes of this collaboration?

The expected outcomes include advancing preclinical studies to support a future investigational new drug application to the FDA for compassionate use in xenotransplantation, potentially leading to innovative treatments for organ failure.

Where can I find more information about Tonix Pharmaceuticals?

More information about Tonix Pharmaceuticals can be found on their official website at www.TonixPharma.com and in the company’s newsroom at https://ibn.fm/TNXP.

What is xenotransplantation and why is it important?

Xenotransplantation involves transplanting organs or cells from one species to another, and it’s important because it offers a potential solution to the shortage of human organs available for transplantation, addressing critical needs in organ failure treatments.

How does Makana Therapeutics’ technology enhance xenotransplantation?

Makana Therapeutics’ genetically engineered pigs, designed without swine leukocyte antigen, have demonstrated improved human compatibility, which is a key advancement in making xenotransplantation more viable and effective.